Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis.

Abstract

Previous studies investigating the association between statin use and survival outcomes in gynecologic cancers have yielded controversial results. We conducted a systematic review and meta-analysis to evaluate the association based on available evidence. We searched the databases of the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and PubMed from inception to January 2017. Studies that evaluated the association between statin use and survival outcomes in gynecologic cancers were included. Pooled hazard ratios (HRs) for overall survival, disease-specific survival and progression-free survival were calculated using a fixed-effects model. A total of 11 studies involving more than 6,920 patients with endocrine-related gynecologic cancers were identified. In a meta-analysis of 7 studies involving 5,449 patients with endocrine-related gynecologic cancers, statin use was linked to improved overall survival (HR, 0.71; 95% confidence interval [CI], 0.63 to 0.80) without significant heterogeneity (I2 = 33.3%). Statin users also had improved disease-specific survival (3 studies, HR, 0.72; 95% CI, 0.58 to 0.90, I2 = 35.1%) and progression-free survival (3 studies, HR, 0.68; 95% CI, 0.49 to 0.93, I2 = 33.6%) in endocrine-related gynecologic cancers. Our findings support that statin use has potential survival benefits for patients with endocrine-related gynecologic cancers. Further large-scale prospective studies are required to validate our findings.

• Authors: Weimin Xie, Li Ning, Yuenan Huang, Yan Liu, Wen Zhang, Yingchao Hu, Jinghe Lang, Jiaxin Yang
• Journal: Oncotarget (Oncotarget) Vol. 8 Issue 25 Pg. 41508-41517 (Jun 20 2017) ISSN: 1949-2553 [Electronic] United States
• PMID: 28489569 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors

Topics

• Disease-Free Survival
• Female
• Genital Neoplasms, Female (drug therapy, mortality, pathology)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (pharmacology, therapeutic use)
• Survival Analysis
• Treatment Outcome